Soleno Therapeutics Inc Stock News

SAN FRANCISCO , Aug. 20, 2025 /PRNewswire/ -- On August 15, 2025, shares in Soleno Therapeutics, Inc. (NASDAQ: SLNO) experienced a significant drop following the release of a highly critical report by Scorpion Capital. Hagens Berman, a national shareholders rights firm, has opened an investigation into Soleno.

ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Soleno Therapeutics, Inc. (“Soleno Therapeutics” or the “Company”) (NASDAQ: SLNO) complied with federal securities laws. On August 15, 2025, Scorpion Capital released a report alleging, among other things, that Soleno Therapeutics' phase 3 clinical trials and withdrawal studies conducted in furtherance of t...

SAN FRANCISCO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. (NASDAQ: SLNO) experienced a significant drop following the release of a highly critical report by Scorpion Capital.

Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Anish Bhatnagar - Chairman, President, CEO & COO James H. MacKaness - CFO & Compliance Officer Meredith Manning - Chief Commercial Officer Conference Call Participants Brian Peter Skorney - Robert W.

Soleno (SLNO) Q2 Revenue Jumps 30%

REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025.

REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. All of the shares are...

REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell $200 million of shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day optio...